loading page

Epicutaneous immunotherapy protects cashew sensitized mice from anaphylaxis
  • +11
  • Benjamin Pelletier,
  • Audrey Perrin,
  • Noémie Assoun,
  • Camille Plaquet,
  • Nathalie Oreal,
  • Laetitia Gaulme,
  • Adeline Bouzereau,
  • Jean-Louis Labernardière,
  • Mélanie Ligouis,
  • Sophie Wavrin,
  • Katie Matthews,
  • Fabrice Porcheray,
  • Hugh Sampson,
  • Pierre-Louis Hervé
Benjamin Pelletier
DBV Technologies
Author Profile
Audrey Perrin
DBV Technologies
Author Profile
Noémie Assoun
DBV Technologies
Author Profile
Camille Plaquet
DBV Technologies
Author Profile
Nathalie Oreal
DBV Technologies
Author Profile
Laetitia Gaulme
DBV Technologies
Author Profile
Adeline Bouzereau
DBV Technologies
Author Profile
Jean-Louis Labernardière
DBV Technologies
Author Profile
Mélanie Ligouis
DBV Technologies
Author Profile
Sophie Wavrin
DBV Technologies
Author Profile
Katie Matthews
DBV Technologies
Author Profile
Fabrice Porcheray
DBV Technologies
Author Profile
Hugh Sampson
DBV Technologies
Author Profile
Pierre-Louis Hervé
DBV Technologies
Author Profile

Abstract

Background: The prevalence of tree nut allergy has increased worldwide, and cashew has become one of the most common food allergens. More critically, cashew allergy is frequently associated with severe anaphylaxis. Despite the high medical need, no approved treatment is available and strict avoidance and preparedness for prompt treatment of allergic reactions are considered dual standard of care. In the meantime, Phase III study results suggest investigational epicutaneous immunotherapy (EPIT) may be a relevant and safe treatment for peanut allergy and may improve the quality of life for many peanut allergic children. Objective: We aimed to evaluate the capacity of EPIT to provide protection against cashew-induced anaphylaxis in a relevant mouse model. Methods: A mouse model of IgE-mediated cashew anaphylaxis was first developed. Based upon this model, the efficacy of EPIT was evaluated by applying patches containing cashew allergens to cashew-sensitized mice. Cashew-specific antibody titers were measured throughout treatment. Treated mice were challenged orally to cashew and anaphylactic symptoms were monitored. Additionally, plasma levels of mast-cell proteases (mMCP)-1/7 were quantified from blood samples collected after challenge to evaluate IgE-induced mast-cell activation. Results: EPIT significantly decreased anaphylactic symptoms following challenge and increased cashew-specific IgG2a (equivalent of human IgG1). Interestingly, this protection was associated with a sharp decrease in mast-cell reactivity. Conclusion: We demonstrate that EPIT markedly reduced IgE-mediated allergic reactions in a mouse model of cashew allergy, which suggests that EPIT may be a relevant approach to treating cashew allergy.

Peer review status:ACCEPTED

09 Jul 2020Submitted to Allergy
10 Jul 2020Submission Checks Completed
10 Jul 2020Assigned to Editor
10 Jul 2020Reviewer(s) Assigned
30 Jul 2020Review(s) Completed, Editorial Evaluation Pending
03 Aug 2020Editorial Decision: Revise Minor
28 Aug 20201st Revision Received
01 Sep 2020Submission Checks Completed
01 Sep 2020Assigned to Editor
06 Sep 2020Reviewer(s) Assigned
17 Sep 2020Review(s) Completed, Editorial Evaluation Pending
19 Sep 2020Editorial Decision: Accept